- Home
- ACRS vs ECBK Comparison
ACRS vs ECBK Comparison
Compare ACRS & ECBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- ECBK
- Stock Information
- Founded
- ACRS 2012
- ECBK 1919
- Country
- ACRS United States
- ECBK United States
- Employees
- ACRS N/A
- ECBK N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- ECBK Banks
- Sector
- ACRS Health Care
- ECBK Finance
- Exchange
- ACRS Nasdaq
- ECBK Nasdaq
- Market Cap
- ACRS 127.6M
- ECBK 137.7M
- IPO Year
- ACRS 2015
- ECBK N/A
- Fundamental
- Price
- ACRS $1.14
- ECBK $15.54
- Analyst Decision
- ACRS Strong Buy
- ECBK
- Analyst Count
- ACRS 7
- ECBK 0
- Target Price
- ACRS $11.67
- ECBK N/A
- AVG Volume (30 Days)
- ACRS 968.2K
- ECBK 23.0K
- Earning Date
- ACRS 05-06-2025
- ECBK 04-28-2025
- Dividend Yield
- ACRS N/A
- ECBK N/A
- EPS Growth
- ACRS N/A
- ECBK N/A
- EPS
- ACRS N/A
- ECBK 0.48
- Revenue
- ACRS $18,720,000.00
- ECBK $26,040,000.00
- Revenue This Year
- ACRS N/A
- ECBK N/A
- Revenue Next Year
- ACRS $425.96
- ECBK N/A
- P/E Ratio
- ACRS N/A
- ECBK $32.38
- Revenue Growth
- ACRS N/A
- ECBK 4.00
- 52 Week Low
- ACRS $0.95
- ECBK $11.39
- 52 Week High
- ACRS $5.17
- ECBK $15.75
- Technical
- Relative Strength Index (RSI)
- ACRS 27.21
- ECBK 62.38
- Support Level
- ACRS $1.05
- ECBK $14.73
- Resistance Level
- ACRS $1.23
- ECBK $15.19
- Average True Range (ATR)
- ACRS 0.11
- ECBK 0.32
- MACD
- ACRS -0.01
- ECBK 0.01
- Stochastic Oscillator
- ACRS 16.82
- ECBK 94.27
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.